Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
NCT06367738
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults. After providing written informed consent, eligible participants, aged between 60 and 85, will be randomly assigned to receive a dose of psilocybin ranging from a microdose to a moderate-to-high dose.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Aging
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 60 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of California, Berkeley
- Last updated on ClinicalTrials.gov
- October 21, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, Berkeley · Berkeley, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.